Session Information
Session Type: ACR Concurrent Abstract Session
Session Time: 2:30PM-4:00PM
acids (n-3 FAs) could be protective against the development of RA. Previously, we found n-3 FAs were
inversely associated with anti-CCP2 positivity in subjects without RA, but at
risk for future RA (Gan 2015). In
this present study, we investigated whether n-3 FAs were also associated with RF
positivity, and if the associations between n-3 FA and these autoantibodies
(Abs) differed by HLA shared epitope (SE) positivity, in subjects at risk for
future RA.
Studies of the Etiology of RA (SERA) cohort includes subjects who are RA-free
by 1987 ACR criteria, but who are at increased risk for future RA, based on
family history of RA. To examine the association between n-3 FA and Ab positivity, we utilized two approaches: 1) a nested
case-control study to determine the
association between RF and anti-CCP2 positivity and percent of n-3 FA in
erythrocyte membranes (RBC n-3 FA%); 2) a cross-sectional study of
the baseline visit of the larger SERA cohort, in which we determined the association between n-3 FA
supplement use and RF and anti-CCP2 positivity. We assessed the role of SE as
an effect modifier using an interaction term in logistic regression models. As
significant n-3 FA*SE interactions were detected for RF, results were stratified
by SE status for both RF and anti-CCP2 for comparison.
several RBC n-3 FA%s were associated with a lower prevalence of RF and anti-CCP
positivity in SE positive subjects but not SE negative subjects (Table 1). In
the larger SERA cohort baseline analyses, n-3 FA supplement use was associated
with a lower prevalence of RF positivity in SE positive subjects, but not SE
negative subjects; similar trends were seen with anti-CCP2 positivity (Table 2).
that n-3 FAs are inversely associated with RF positivity in SE positive subjects
with a familial risk of RA. In combination with our prior work that found n-3
FAs are inversely associated with anti-CCP2 positivity, these data suggests a potential
protective effect of n-3 FAs against broader RA-related autoimmunity. Furthermore,
the protective effect of n-3 FAs on RA-related autoimmunity may be most
pronounced in SE positive subjects. Our findings could be explained by the
ability of n-3 FAs to change the conformation of membrane MHC class II molecules
and alter antigen presentation and Ab generation (Hughes
1996, Rockett 2015), or other adaptive immune
mechanisms yet to be identified. This needs further investigation, as it could
lead to the use of n-3 FAs in the prevention of RA.
Table 1: Nested case-control study associations between increasing RBC n-3 FA% and the outcomes of anti-CCP2 and RF by shared epitope status (27 RF positive subjects, 40 anti-CCP2 positive subjects, and 69 antibody negative subjects).
|
|||||||||
|
RF
|
|
|||||||
|
SE Positive (n=11 RF pos.)
|
SE Negative (n=16 RF pos.)
|
|
||||||
RBC n-3 FA%
|
OR*
|
95% CI
|
p
|
OR*
|
95% CI
|
p
|
pinter
|
||
Total n-3 FA
|
0.27
|
0.10-0.79
|
0.02
|
0.94
|
0.49-1.78
|
0.84
|
0.04
|
||
ALA(18:3n-3)
|
1.02
|
0.54-1.93
|
0.94
|
1.21
|
0.59-2.48
|
0.60
|
0.73
|
||
EPA(20:5n-3)
|
0.43
|
0.10-1.82
|
0.25
|
0.98
|
0.55-1.75
|
0.95
|
0.28
|
||
DPA(22:5n-3)
|
0.39
|
0.17-0.89
|
0.03
|
0.74
|
0.35-1.56
|
0.42
|
0.26
|
||
DHA(22:6n-3)
|
0.34
|
0.13-0.91
|
0.03
|
1.02 |
0.52-1.98
|
0.96
|
0.06
|
||
EPA+DHA
|
0.31
|
0.10-0.91
|
0.03
|
0.99 |
0.53-1.87 |
0.98 |
0.06 |
||
|
Anti-CCP2
|
|
|||||||
|
SE Positive (n=24 Anti-CCP2 pos.)
|
SE Negative (n=16 Anti-CCP2 pos.)
|
|
||||||
RBC n-3 FA%
|
OR*
|
95% CI
|
p
|
OR*
|
95% CI
|
p
|
pinter
|
||
Total n-3 FA
|
0.42
|
0.20-0.89
|
0.03
|
0.74
|
0.39-1.40
|
0.35
|
0.24
|
||
ALA(18:3n-3)
|
0.90
|
0.24-1.50
|
0.68
|
0.68
|
0.27-1.71
|
0.41
|
0.60
|
||
EPA(20:5n-3)
|
0.27
|
0.09-0.83
|
0.02
|
0.61
|
0.32-1.17
|
0.14
|
0.20
|
||
DPA(22:5n-3)
|
0.84
|
0.47-1.52
|
0.56
|
0.92
|
0.46-1.83
|
0.80
|
0.85
|
||
DHA(22:6n-3)
|
0.47
|
0.24-0.92
|
0.03
|
0.79
|
0.42-1.51
|
0.48
|
0.25
|
||
EPA+DHA
|
0.40
|
0.18-0.85
|
0.02
|
0.73
|
0.39-1.37
|
0.33
|
0.20
|
||
|
|||||||||
|
|||||||||
|
RF
|
|
|||||||
|
SE Positive (n=60 RF pos.)
|
SE Negative (n=55 RF pos.)
|
|
||||||
n-3 FA Supplement
|
OR*
|
95% CI
|
p
|
OR*
|
95% CI
|
p
|
pinter
|
||
Yes vs. No |
0.35 |
0.15-0.82 |
0.02 |
1.21 |
0.64-2.28 |
0.56 |
0.02 |
||
|
|
|
|||||||
|
Anti-CCP2
|
|
|||||||
|
SE Positive (n=27 Anti-CCP2 pos.)
|
SE Negative (n=17 Anti-CCP2 pos.)
|
|
||||||
n-3 FA Supplement
|
OR*
|
95% CI
|
p
|
OR*
|
95% CI
|
p
|
pinter
|
||
Yes vs. No |
0.28 |
0.07-1.20 |
0.09 |
1.11 |
0.35-3.49 |
0.83 |
0.14 |
||
|
|||||||||
To cite this abstract in AMA style:
Gan RW, Demoruelle MK, Deane KD, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Fingerlin T, Zerbe GO, Clare-Salzler MJ, Holers VM, Norris JM. Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/omega-3-fatty-acids-are-associated-with-a-lower-prevalence-of-autoantibody-positivity-in-hla-dr-shared-epitope-positive-subjects-who-are-at-increased-risk-for-future-ra/. Accessed .« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/omega-3-fatty-acids-are-associated-with-a-lower-prevalence-of-autoantibody-positivity-in-hla-dr-shared-epitope-positive-subjects-who-are-at-increased-risk-for-future-ra/